The Magazine for Sleep Professionals
Saturday, September 26, 2026
Nyxoah SA has announced the DREAM U.S. pivotal study achieved a statistically significant reduction in the co-primary endpoints of 12-month AHI responder rate, per the Sher criteria, and ODI responder rate, both on an ITT basis. The DREAM study is a pivotal trial being conducted under an investigational device exemption […]
It’s well understood and accepted that sleep position, in particular the supine position in which a person sleeps on their back with their face and abdomen facing upwards, is associated with an increase in sleep-disordered breathing.1 While over half of all cases of obstructive sleep apnea (OSA) are classified as […]
As the prevalence of atrial fibrillation (AF) continues to rise, particularly among the aging population, its connection with obstructive sleep apnea (OSA) has become increasingly evident.1 Patients with AF seeking treatment for OSA often present with a complex medical history that includes a number of comorbidities, such as hypertension, acid […]
EnsoData, a pioneer in healthcare AI, achieved FDA 510(k) clearance for groundbreaking technology that enables AI-powered sleep diagnosis using FDA-cleared pulse oximetry (pulse ox) devices. Powered by EnsoSleep PPG scoring, widely available and wearable pulse ox technology can be deployed for a high-quality, accessible, and cost-effective approach to diagnosing sleep […]
ResMed launched its AirCurve 11 series devices, the company’s newest bilevel devices that use two levels of support, inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP), combined with digital technology to make it easier for healthcare providers to treat sleep apnea and to help patients start and […]
Samsung Electronics announced that the sleep apnea feature1 on the Samsung Health Monitor app2 has received De Novo authorization from the U.S. Food and Drug Administration (FDA). This feature, which detects signs of sleep apnea using a compatible Samsung Galaxy Watch and phone, was the first of its kind to be authorized […]
Takeda has announced positive topline results from a randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1. Narcolepsy is a chronic, rare neurological disorder of central hypersomnolence with significant unmet need despite multiple approved therapies. It is […]
Fibromyalgia is a complex chronic condition associated with pain, myalgias, and arthralgias, as well as a constitution of other debilitating symptoms such as fatigue and cognitive, gastrointestinal, sleep, and mood issues.1 Sleep disturbances are a hallmark feature of the condition and have a significant bidirectional relationship with other symptomatology, especially […]
Sleep Specialists, LLC, the manufacturer of Zzoma® positional therapy for obstructive sleep apnea (OSA), and iSleep Physicians, a leading virtual sleep specialist practice, have announced a collaboration to improve access to effective OSA treatment options for patients nationwide, offering a comfortable and potentially mask-free alternative to traditional CPAP therapy. Zzoma […]
